TaiMed Biologics Statistics
Total Valuation
TaiMed Biologics has a market cap or net worth of TWD 21.81 billion. The enterprise value is 20.21 billion.
Market Cap | 21.81B |
Enterprise Value | 20.21B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
TaiMed Biologics has 273.01 million shares outstanding. The number of shares has increased by 2.22% in one year.
Shares Outstanding | 273.01M |
Shares Change (YoY) | +2.22% |
Shares Change (QoQ) | +7.73% |
Owned by Insiders (%) | 1.46% |
Owned by Institutions (%) | 5.29% |
Float | 185.52M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 49.02 |
PS Ratio | 32.14 |
PB Ratio | 5.21 |
P/FCF Ratio | 188.86 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -184.13 |
EV / Sales | 31.49 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 174.94 |
Financial Position
The company has a current ratio of 25.38, with a Debt / Equity ratio of 12.82.
Current Ratio | 25.38 |
Quick Ratio | 16.56 |
Debt / Equity | 12.82 |
Debt / EBITDA | 12.78 |
Debt / FCF | 4.65 |
Interest Coverage | -7.65 |
Financial Efficiency
Return on equity (ROE) is -3.21% and return on invested capital (ROIC) is -1.66%.
Return on Equity (ROE) | -3.21% |
Return on Assets (ROA) | -1.46% |
Return on Capital (ROIC) | -1.66% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.14 |
Inventory Turnover | 0.29 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.25% in the last 52 weeks. The beta is 0.35, so TaiMed Biologics's price volatility has been lower than the market average.
Beta (5Y) | 0.35 |
52-Week Price Change | -13.25% |
50-Day Moving Average | 82.03 |
200-Day Moving Average | 86.68 |
Relative Strength Index (RSI) | 43.81 |
Average Volume (20 Days) | 628,302 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TaiMed Biologics had revenue of TWD 641.66 million and -109.74 million in losses. Loss per share was -0.43.
Revenue | 641.66M |
Gross Profit | 272.57M |
Operating Income | -108.09M |
Pretax Income | -109.74M |
Net Income | -109.74M |
EBITDA | 39.78M |
EBIT | -108.09M |
Loss Per Share | -0.43 |
Balance Sheet
The company has 2.14 billion in cash and 537.15 million in debt, giving a net cash position of 1.61 billion or 5.89 per share.
Cash & Cash Equivalents | 2.14B |
Total Debt | 537.15M |
Net Cash | 1.61B |
Net Cash Per Share | 5.89 |
Equity (Book Value) | 4.19B |
Book Value Per Share | 15.34 |
Working Capital | 3.43B |
Cash Flow
In the last 12 months, operating cash flow was 119.88 million and capital expenditures -4.38 million, giving a free cash flow of 115.50 million.
Operating Cash Flow | 119.88M |
Capital Expenditures | -4.38M |
Free Cash Flow | 115.50M |
FCF Per Share | 0.42 |
Margins
Gross margin is 42.48%, with operating and profit margins of -16.85% and -17.10%.
Gross Margin | 42.48% |
Operating Margin | -16.85% |
Pretax Margin | -17.10% |
Profit Margin | -17.10% |
EBITDA Margin | 6.20% |
EBIT Margin | -16.85% |
FCF Margin | 18.00% |
Dividends & Yields
TaiMed Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.22% |
Shareholder Yield | -2.22% |
Earnings Yield | -0.54% |
FCF Yield | 0.53% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |